New cancer drug enters human testing for Tough-to-Treat tumors
NCT ID NCT07069062
First seen Jan 03, 2026 · Last updated Apr 18, 2026 · Updated 17 times
Summary
This early-stage trial is testing a new drug called HY0001a in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose, understand how the drug moves through the body, and see if it shows any early signs of shrinking tumors. The study will enroll 261 adults with cancers like esophageal cancer, lung cancer, and others.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100143, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.